Structure-activity relationship of captopril derivatives as New Delhi metallo beta-lactamase 1 inhibitors
Review paper
DOI:
https://doi.org/10.5599/admet.3304Keywords:
Zinc binding group, fluorinated analogues, stereochemical effects, pyrrolidine ring, mercaptopropionamideAbstract
Background and purpose New Delhi Metallo beta-lactamase-1 (NDM-1) is a zinc-dependent enzyme that confers resistance to several antibiotics; therefore, there is an urgent requirement for effective inhibitors. Captopril has been exploited as a scaffold in the design of NDM-1 inhibitors; however, a comparative evaluation of these derivatives from structure activity relationship perspective has not been conducted. This review aimed to evaluate captopril-derived NDM-1 inhibitors and to identify possible structure-activity relationships that govern their NDM-1 inhibitory action. Experimental approach: The literature was searched in a structured manner using scholarly databases to locate original studies that reported captopril derivatives and evaluated them in vitro against NDM-1 with the explicit reporting of the inhibitory concentration values (IC50). Eligible studies were filtered using predefined criteria and analysed using a qualitative approach, because heterogeneity in assay conditions and experimental methods prevented a direct quantitative comparison across studies. Important findings: The activity of captopril derivatives depends on the free thiol group (masking it reduces activity), with stereochemistry governing optimal binding orientation within the NDM-1 active site, hydrophobic substitutions enhance activity only within steric limits, and the carboxylate motif serves as a secondary anchoring feature. Conclusion: Captopril emerges as a promising scaffold for NDM-1 inhibitors and reveals significant structural features associated with NDM-1 inhibitors. Despite limited in vivo data and heterogeneity in assay conditions, the findings provide a rational framework for optimizing captopril-inspired NDM-1 inhibitors.
Downloads
References
[1] D.T. Davies, M. Everett. Designing inhibitors of β-lactamase enzymes to overcome carbapenem resistance in Gram-negative bacteria. Accounts of Chemical Research 54 (2021) 2055-2064. https://doi.org/10.1021/acs.accounts.0c00863 DOI: https://doi.org/10.1021/acs.accounts.0c00863
[2] D. Yong, M.A. Toleman, C.G. Giske, H.S. Cho, K. Sundman, K. Lee, T.R. Walsh. Characterization of a new Metallo-β-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrobial Agents and Chemotherapy 53 (2009) 5046-5054. https://doi.org/10.1128/AAC.00774-09 DOI: https://doi.org/10.1128/AAC.00774-09
[3] K.K. Kumarasamy, M.A. Toleman, T.R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, U. Chaudhary, M. Doumith, C.G. Giske, S. Irfan, P. Krishnan, A.V. Kumar, S. Maharjan, S. Mushtaq, T. Noorie, D.L. Paterson, A. Pearson, C. Perry, R. Pike, B. Rao, U. Ray, J.B. Sarma, M. Sharma, E. Sheridan, M.A. Thirunarayan, J. Turton, S. Upadhyay, M. Warner, W. Welfare, D.M. Livermore, N. Woodford. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases 10 (2010) 597-602. https://doi.org/10.1016/S1473-3099(10)70143-2 DOI: https://doi.org/10.1016/S1473-3099(10)70143-2
[4] T. Wang, K. Xu, L. Zhao, R. Tong, L. Xiong, J. Shi. Recent research and development of NDM-1 inhibitors. European Journal of Medicinal Chemistry 223 (2021) 113667. https://doi.org/10.1016/j.ejmech.2021.113667 DOI: https://doi.org/10.1016/j.ejmech.2021.113667
[5] S.M. Drawz, R.A. Bonomo. Three decades of β-lactamase inhibitors. Clinical Microbiology Reviews 23 (2010) 160-201. https://doi.org/10.1128/CMR.00037-09 DOI: https://doi.org/10.1128/CMR.00037-09
[6] P. Nordmann, T. Naas, L. Poirel. Global spread of carbapenemase-producing Enterobacteriaceae. Emerging Infectious Diseases 17 (2011) 1791-1798. https://doi.org/10.3201/eid1710.110655 DOI: https://doi.org/10.3201/eid1710.110655
[7] M. Rus, M. Licker, C. Musuroi, E. Seclaman, D. Muntean, N. Cirlea, A. Tamas, S. Vulpie, F.G. Horhat, L. Baditoiu. Distribution of NDM-1 carbapenemase-producing Proteeae strains on high-risk hospital wards. Infection and Drug Resistance 13 (2020) 4751-4761. https://doi.org/10.2147/IDR.S280977 DOI: https://doi.org/10.2147/IDR.S280977
[8] Z. Sun, L. Hu, B. Sankaran, B.V.V. Prasad, T. Palzkill. Differential active site requirements for NDM-1 β-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics. Nature Communications 9 (2018) 4524. https://doi.org/10.1038/s41467-018-06839-1 DOI: https://doi.org/10.1038/s41467-018-06839-1
[9] Y. Guo, J. Wang, G. Niu, W. Shui, Y. Sun, H. Zhou, Y. Zhang, C. Yang, Z. Lou, Z. Rao. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug. Protein & Cell 2 (2011) 384-394. https://doi.org/10.1007/s13238-011-1055-9 DOI: https://doi.org/10.1007/s13238-011-1055-9
[10] M. Al Musawa, C.R. Bleick, S.R. Herbin, K.E. Caniff, S.R. Van Helden, M.J. Rybak. Aztreonam-avibactam: the dynamic duo against multidrug-resistant gram-negative pathogens. Pharmacotherapy 44 (2024) 927-938. https://doi.org/10.1002/phar.4629 DOI: https://doi.org/10.1002/phar.4629
[11] P. Linciano, L. Cendron, E. Gianquinto, F. Spyrakis, D. Tondi. Ten years with New Delhi metallo-β-lactamase-1 (NDM-1): from structural insights to inhibitor design. ACS Infectious Diseases 5 (2019) 9-34. https://doi.org/10.1021/acsinfecdis.8b00247 DOI: https://doi.org/10.1021/acsinfecdis.8b00247
[12] Y. Yang, Y. Guo, Y. Zhou, Y. Gao, X. Wang, J. Wang, X. Niu. Discovery of a novel natural allosteric inhibitor that targets NDM-1 against Escherichia coli. Frontiers in Pharmacology 11 (2020) 581001. https://doi.org/10.3389/fphar.2020.581001 DOI: https://doi.org/10.3389/fphar.2020.581001
[13] B.A. Fomda, A. Khan, D. Zahoor. NDM-1 (New Delhi Metallo beta lactamase-1) producing Gram-negative bacilli: emergence & clinical implications. Indian Journal of Medical Research 140 (2014) 672-678. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311323/
[14] X. Li, D. Zhao, W. Li, J. Sun, X. Zhang. Enzyme inhibitors: the best strategy to tackle superbug NDM-1 and its variants. International Journal of Molecular Sciences 23 (2021) 197. https://doi.org/10.3390/ijms23010197 DOI: https://doi.org/10.3390/ijms23010197
[15] P.W. Thomas, T. Spicer, M. Cammarata, J.S. Brodbelt, P. Hodder, W. Fast. An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening. Bioorganic & Medicinal Chemistry 21 (2013) 3138-3146. https://doi.org/10.1016/j.bmc.2013.03.031 DOI: https://doi.org/10.1016/j.bmc.2013.03.031
[16] S. Sharma, S. Sharma, P.P. Singh, I.A. Khan. Potential inhibitors against NDM-1 type Metallo-β-lactamases: an overview. Microbial Drug Resistance 26 (2020) 1568-1588. https://doi.org/10.1089/mdr.2019.0315 DOI: https://doi.org/10.1089/mdr.2019.0315
[17] P.W. Thomas, M. Cammarata, J.S. Brodbelt, W. Fast. Covalent inhibition of New Delhi Metallo-β-lactamase-1 (NDM-1) by cefaclor. ChemBioChem 15 (2014) 2541-2548. https://doi.org/10.1002/cbic.201402268 DOI: https://doi.org/10.1002/cbic.201402268
[18] Chiou, S. Wan, K.F. Chan, P.K. So, D. He, E.W. Chan, T. Chan, K. Wong, J. Tao, S. Chen. Ebselen as a potent covalent inhibitor of New Delhi Metallo-β-lactamase (NDM-1). Chemical Communications 51 (2015) 9543-9546. https://doi.org/10.1039/c5cc02594j DOI: https://doi.org/10.1039/C5CC02594J
[19] A. Krajnc, J. Brem, P. Hinchliffe, K. Calvopiña, T.D. Panduwawala, P.A. Lang, J.J.A.G. Kamps, J.M. Tyrrell, E. Widlake, B.G. Saward, T.R. Walsh, J. Spencer, C.J. Schofield. Bicyclic boronate VNRX-5133 inhibits Metallo- and serine-β-lactamases. Journal of Medicinal Chemistry 62 (2019) 8544-8556. https://doi.org/10.1021/acs.jmedchem.9b00911 DOI: https://doi.org/10.1021/acs.jmedchem.9b00911
[20] R. Azumah, J. Dutta, A.M. Somboro, M. Ramtahal, L. Chonco, R. Parboosing, L.A. Bester, H.G. Kruger, T. Naicker, S.Y. Essack, T. Govender. In vitro evaluation of metal chelators as potential Metallo-β-lactamase inhibitors. Journal of Applied Microbiology 120 (2016) 860-867. https://doi.org/10.1111/jam.13085 DOI: https://doi.org/10.1111/jam.13085
[21] S. Fullington, Z. Cheng, C. Thomas, C. Miller, K. Yang, L.C. Ju, A. Bergstrom, B.A. Shurina, S.L. Bretz, R.C. Page, D.L. Tierney, M.W. Crowder. An integrated biophysical approach to discovering mechanisms of NDM-1 inhibition for several thiol-containing drugs. Journal of Biological Inorganic Chemistry 25 (2020) 717-727. https://doi.org/10.1007/s00775-020-01794-z DOI: https://doi.org/10.1007/s00775-020-01794-z
[22] C. Chen, D. Wang, K.W. Yang. Thiols as a privileged scaffold against Metallo-β-lactamases. Privileged Scaffolds in Drug Discovery, Academic Press, Cambridge, USA, 2023, p. 301-318. https://doi.org/10.1016/B978-0-443-18611-0.00036-X DOI: https://doi.org/10.1016/B978-0-443-18611-0.00036-X
[23] C. Kaya, J. Konstantinović, A.M. Kany, A. Andreas, J.S. Kramer, S. Brunst, L. Weizel, M.J. Rotter, D. Frank, S. Yahiaoui, R. Müller, R.W. Hartmann, J. Haupenthal, E. Proschak, T.A. Wichelhaus, A.K.H. Hirsch. N-Aryl mercaptopropionamides as broad-spectrum inhibitors of Metallo-β-lactamases. Journal of Medicinal Chemistry 65 (2022) 3913-3922. https://doi.org/10.1021/acs.jmedchem.1c01755 DOI: https://doi.org/10.1021/acs.jmedchem.1c01755
[24] Brem, R. Cain, S. Cahill, M.A. McDonough, I.J. Clifton, J.C. Jiménez-Castellanos, M.B. Avison, J. Spencer, C.W.G. Fishwick, C.J. Schofield. Structural basis of Metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nature Communications 7 (2016) 12406. https://doi.org/10.1038/ncomms12406 DOI: https://doi.org/10.1038/ncomms12406
[25] S.M. Rudresh, G.S. Ravi, Y. Raksha. In vitro efficacy of biocompatible zinc ion chelating molecules as Metallo-β-lactamase inhibitor among NDM producing Escherichia coli. Journal of Laboratory Physicians 15 (2023) 62-68. https://doi.org/10.1055/s-0042-1751317 DOI: https://doi.org/10.1055/s-0042-1751317
[26] RCSB Protein Data Bank. Crystal structure of NDM-1 in complex with L-captopril. https://www.rcsb.org/structure/5ZIO (accessed January 17, 2026)
[27] J. Su, J. Liu, C. Chen, Y. Zhang, K. Yang. Ebsulfur as a potent scaffold for inhibition and labelling of New Delhi Metallo-β-lactamase-1 in vitro and in vivo. Bioorganic Chemistry 84 (2019) 192-201. https://doi.org/10.1016/j.bioorg.2018.11.035 DOI: https://doi.org/10.1016/j.bioorg.2018.11.035
[28] Y.N. Chang, Y. Xiang, Y.J. Zhang, W.M. Wang, C. Chen, P. Oelschlaeger, K.W. Yang. Carbamylmethyl mercaptoacetate thioether: a novel scaffold for the development of L1 Metallo-β-lactamase inhibitors. ACS Medicinal Chemistry Letters 8 (2017) 527-532. https://doi.org/10.1021/acsmedchemlett.7b00058 DOI: https://doi.org/10.1021/acsmedchemlett.7b00058
[29] P. Hinchliffe, C.A. Tanner, A.P. Krismanich, G. Labbé, V.J. Goodfellow, L. Marrone, A.Y. Desoky, K. Calvopiña, E.E. Whittle, F. Zeng, M.B. Avison, N.C. Bols, S. Siemann, J. Spencer, G.I. Dmitrienko. Structural and kinetic studies of the potent inhibition of metallo-β-lactamases by 6-phosphonomethylpyridine-2-carboxylates. Biochemistry 57 (2018) 1880-1892. https://doi.org/10.1021/acs.biochem.7b01299 DOI: https://doi.org/10.1021/acs.biochem.7b01299
[30] Y. Yusof, D.T.C. Tan, O.K. Arjomandi, G. Schenk, R.P. McGeary. Captopril analogues as Metallo-β-lactamase inhibitors. Bioorganic & Medicinal Chemistry Letters 26 (2016) 1589-1593. https://doi.org/10.1016/j.bmcl.2016.02.007 DOI: https://doi.org/10.1016/j.bmcl.2016.02.007
[31] E. Noumi, M. Snoussi, N. Bouali, M.M. Alshammari, H.N. Altayb, M. Afzal, V. De Feo. Structure-based virtual screening, molecular docking, and MD simulation studies: an in-silico approach for identifying potential MBL inhibitors. PLoS ONE 20 (2025) e0324836. https://doi.org/10.1371/journal.pone.0324836 DOI: https://doi.org/10.1371/journal.pone.0324836
[32] D. Dutta, S. Mishra. L-captopril and its derivatives as potential inhibitors of microbial enzyme DapE: a combined approach of drug repurposing and similarity screening. Journal of Molecular Graphics and Modelling 84 (2018) 82-89. https://doi.org/10.1016/j.jmgm.2018.06.004 DOI: https://doi.org/10.1016/j.jmgm.2018.06.004
[33] V.G. Grigorenko, M.G. Khrenova, I.P. Andreeva, M.Y. Rubtsova, A.I. Lev, T.S. Novikova, E.V. Detusheva, N.K. Fursova, I.A. Dyatlov, A.M. Egorov. Drug repurposing of unithiol: inhibition of Metallo-β-lactamases for the treatment of carbapenem-resistant Gram-negative bacterial infections. International Journal of Molecular Sciences 23 (2022) 1834. https://doi.org/10.3390/ijms23031834 DOI: https://doi.org/10.3390/ijms23031834
[34] Y. Liu, Z. Tong, J. Shi, R. Li, M. Upton, Z. Wang. Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria. Theranostics 11 (2021) 4910-4928. https://doi.org/10.7150/thno.56205 DOI: https://doi.org/10.7150/thno.56205
[35] D.T. King, L.J. Worrall, R. Gruninger, N.C.J. Strynadka. New Delhi Metallo-β-lactamase: structural insights into β-lactam recognition and inhibition. Journal of the American Chemical Society 134 (2012) 11362-11365. https://doi.org/10.1021/ja303579d DOI: https://doi.org/10.1021/ja303579d
[36] T. Yu, A. Malik, N. Anuwongcharoen, W. Eiamphungporn, C. Nantasenamat, T. Piacham. Towards combating antibiotic resistance by exploring the quantitative structure-activity relationship of NDM-1 inhibitors. EXCLI Journal 21 (2022) 1331-1341. https://doi.org/10.17179/excli2022-5380
[37] D.T. King. Protecting our beta-lactam antibiotic assets: structural investigation of beta-lactamases. PhD Thesis, University of British Columbia, Vancouver, Canada, 2016. https://doi.org/10.14288/1.0222998
[38] G. Ma, S. Wang, K. Wu, W. Zhang, A. Ahmad, Q. Hao, X. Lei, H. Zhang. Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors. Bioorganic & Medicinal Chemistry 29 (2021) 115902. https://doi.org/10.1016/j.bmc.2020.115902 DOI: https://doi.org/10.1016/j.bmc.2020.115902
[39] Brem, S.S. van Berkel, D. Zollman, S.Y. Lee, O. Gileadi, P.J. McHugh, T.R. Walsh, M.A. McDonough, C.J. Schofield. Structural basis of Metallo-β-lactamase inhibition by captopril stereoisomers. Antimicrobial Agents and Chemotherapy 60 (2015) 142-150. https://doi.org/10.1128/AAC.01335-15 DOI: https://doi.org/10.1128/AAC.01335-15
[40] N. Li, Y. Xu, Q. Xia, C. Bai, T. Wang, L. Wang, D. He, N. Xie, L. Li, J. Wang, H.G. Zhou, F. Xu, C. Yang, Q. Zhang, Z. Yin, Y. Guo, Y. Chen. Simplified captopril analogues as NDM-1 inhibitors. Bioorganic & Medicinal Chemistry Letters 24 (2014) 386-389. https://doi.org/10.1016/j.bmcl.2013.10.068 DOI: https://doi.org/10.1016/j.bmcl.2013.10.068
[41] Z. Meng, M.L. Tang, L. Yu, Y. Liang, J. Han, C. Zhang, F. Hu, J.M. Yu, X. Sun. Novel mercapto propionamide derivatives with potent New Delhi Metallo-β-lactamase-1 inhibitory activity and low toxicity. ACS Infectious Diseases 5 (2019) 903-916. https://doi.org/10.1021/acsinfecdis.8b00366 DOI: https://doi.org/10.1021/acsinfecdis.8b00366
[42] A.I. Alfano, S. Pelliccia, S. Barone, L. Cutarella, S.M.I. Cancade, V. Baia, E. Cassese, P. Russomanno, N. Messano, D. Frank, L. Weizel, M.J. Rotter, S. Brunst, T.A. Wichelhaus, E. Proschak, D. Tedesco, M. Mori, J.D. Docquier, V. Summa, M. Brindisi. Sustainable Joullié-Ugi and continuous flow implementation led to novel captopril-inspired broad-spectrum Metallo-β-lactamase inhibitors. Journal of Medicinal Chemistry 68 (2025) 17236-17257. https://doi.org/10.1021/acs.jmedchem.5c00750 DOI: https://doi.org/10.1021/acs.jmedchem.5c00750
[43] A. Kondratieva, K. Palica, C. Frøhlich, R.R. Hovd, H.K.S. Leiros, M. Erdelyi, A. Bayer. Fluorinated captopril analogues inhibit Metallo-β-lactamases and facilitate structure determination of NDM-1 binding pose. European Journal of Medicinal Chemistry 266 (2024) 116140. https://doi.org/10.1016/j.ejmech.2024.116140 DOI: https://doi.org/10.1016/j.ejmech.2024.116140
[44] Brem, S.S. van Berkel, W. Aik, A.M. Rydzik, M.B. Avison, I. Pettinati, K.D. Umland, A. Kawamura, J. Spencer, T.D.W. Claridge, M.A. McDonough, C.J. Schofield. Rhodanine hydrolysis leads to potent thioenolate-mediated Metallo-β-lactamase inhibition. Nature Chemistry 6 (2014) 1084-1090. https://doi.org/10.1038/nchem.2110 DOI: https://doi.org/10.1038/nchem.2110
[45] S.S. van Berkel, J. Brem, A.M. Rydzik, R. Salimraj, R. Cain, A. Verma, R.J. Owens, C.W.G. Fishwick, J. Spencer, C.J. Schofield. Assay platform for clinically relevant Metallo-β-lactamases. Journal of Medicinal Chemistry 56 (2013) 6945-6953. https://doi.org/10.1021/jm400769b DOI: https://doi.org/10.1021/jm400769b
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ikhlas Jarrar
This work is licensed under a Creative Commons Attribution 4.0 International License.
